^
    Back
    Association details:
    Biomarker:FER overexpression
    Cancer:Breast Cancer
    Regimen: (doxorubicin hydrochloride + cyclophosphamide + docetaxel)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Cell Rep
    Title:

    FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancer

    Published date:
    04/05/2022
    Excerpt:
    We analyzed gene expression data from the MATADOR study (van Rossum et al., 2018 ), a randomized phase III clinical trial in which 664 patients were treated with either adjuvant dose-dense doxorubicin + cyclophosphamide (ddAC) or AC combined with docetaxel (TAC)...high FER levels correlated with an increased probability of recurrence-free survival (RFS) following taxane-containing treatment, compared with ddAC-only treatment (adjHR = 0.48; 95% CI: 0.24–0.96; p = 0.039) (Figure 2E).
    DOI:
    10.1016/j.celrep.2022.110584